Timosaponin A-III is widely studied for its potential in cancer therapy due to its ability to induce apoptosis and inhibit proliferation in various cancer cell lines, including breast, colon, and liver cancers. It has shown anti-inflammatory effects by suppressing key inflammatory mediators like NF-κB and COX-2, making it a candidate for treating chronic inflammatory diseases. The compound also exhibits neuroprotective properties, enhancing cognitive function in models of Alzheimer’s disease by reducing amyloid-beta accumulation and oxidative stress in brain cells. Additionally, Timosaponin A-III demonstrates antidiabetic activity by improving insulin sensitivity and glucose uptake in cellular and animal models. Its ability to modulate autophagy and cell cycle progression further supports its role in therapeutic development for metabolic and neurodegenerative disorders.